Perampanel as add-on therapy in epilepsy treatment: PERBONN, a retrospective long-term real-world study

Perampanel as add-on therapy in epilepsy treatment: PERBONN, a retrospective long-term real-world study - PERBONN

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00039339

Enrollment

500

Registered

2026-03-23

Start date

2025-12-01

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

G40

Interventions

Group 1: Adult patients who were treated with perampanel (PER) as adjunctive therapy for the first time between August 1, 2012, and August 1, 2016.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Adult patients who were administered perampanel (PER) as adjunctive therapy for the first time at our clinic between August 1, 2012, and August 1, 2016.

Exclusion criteria

Exclusion criteria: Age under 18 years, no additional medication with perampanel

Design outcomes

Primary

Measure	Time frame
Follow-up examinations after 6, 12, 60, and 60+ months: Continuation of PER adjunctive therapy, objective and subjective assessment of seizure control under PER therapy, occurrence of side effects	—

Secondary

Measure	Time frame
Influence of individual personal and disease-related factors on the above variables	—

Countries

Germany

Contacts

Public ContactAttila Racz

Klinik und Poliklinik für Epileptologie, Universitätsklinikum Bonn

attila.racz@ukbonn.de+49 228 287 15709

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Apr 4, 2026